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The spinocerebellar ataxias (SCAs), also referred to as autosomal 
dominant cerebellar ataxias (ADCAs), are inherited diseases 
characterised by cerebellar and spinal cord degeneration. There 
are at least 31 known forms of SCA. The SCAs are clinically 
heterogeneous, with the age of onset, severity and rate of disease 
progression differing significantly between individuals.1 Onset of 
clinical symptoms usually occurs between the third and fifth decade, 
although cases of onset in early childhood and over 60 years of age 
have been reported, and typically progress to death within 10 - 20 
years.2 A subset of the SCAs is caused by the expansion of a CAG 
repeat motif in the disease-causing gene, resulting in an expanded 
polyglutamine tract within the corresponding protein. SCA1, 2, 3, 
6, 7 and 17 are therefore additionally classified as polyglutamine 
diseases. Table 1 summarises the clinical features of the more 
common types of SCA in South Africa (SA).
The prevalence of the SCAs in Europe is estimated to be 1 - 3 
per 100 000.1 Although studies have investigated SCA frequency in 
other countries, only one has focused on the epidemiology of the 
polyglutamine SCAs in southern Africa. In 2003, Bryer and colleagues 
examined the spectrum and frequencies of the polyglutamine SCAs 
in SA through clinical and molecular evaluation of 54 families.3 
This study includes the most recent epidemiological figures of the 
frequency of the polyglutamine SCAs in SA.
Methods
Patients from the SA public or private health sectors who presented 
with clinical signs of SCA were referred to the molecular diagnostics 
laboratory of the National Health Laboratory Service (NHLS) in 
Cape Town, the only centre in SA offering molecular genetic testing 
for the polyglutamine SCAs (SCA1, 2, 3, 6, 7 and 17) since testing 
was initiated in 1987.
The QIAamp DNA Blood Mini kit (Qiagen) was used for genomic 
DNA isolation from fresh or frozen blood from each individual. The 
CAG repeat region within each causative gene was amplified using 
a multiplex PCR method,4 followed by capillary electrophoresis on 
the ABI 3100 Genetic Analyzer (Applied Biosystems). SCA17 repeat 
sizes were determined using previously described methods.5 The sizes 
of the repeats were determined by comparison with the GeneScan 
500 Rox Size Standard (Applied Biosystems). Each run included 
positive control samples of known CAG repeat length. Samples with 
homozygous alleles in the normal repeat range were not re-tested. 
The NHLS testing laboratory undergoes annual external quality 
assessments (EQA) by the European Molecular Genetics Quality 
Network (EMQN).
Paper-based diagnostic reports in the laboratory at the University 
of Cape Town (UCT) and the NHLS electronic patient record database 
for 1987 - 2011 were mined for information regarding the molecular 
diagnosis, ethnicity (reported by the referring clinician) and CAG 
repeat length for each individual patient referral. Ethical approval 
was granted by the institutional Human Research Ethics Committee 
(HREC REF 229/2010, renewed in 2011). Where applicable, written 
informed consent was obtained for biological material intended for 
research purposes.
Results
Distribution of SCAs in SA
Of the 1 113 individuals tested for the panel of 5 polyglutamine SCAs 
over 24 years, 245 (22%) were identified with pathogenic expanded 
repeats in 1 of the 5 tested SCA loci (Table 2). With a population of 50.5 
million in 2011,6 the annual incidence of the polyglutamine SCAs in 
SA is therefore estimated to be approximately 2.02/10 000 000 per year. 
The molecular testing laboratory is not involved in patient management 
and follow-up, and could not comment on the current level of survival 
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of these patients. Similar to 2003 data,3 SCA1 and 7 accounted for most 
positive cases (48.8% and 26.6%, respectively). Most individuals affected 
with SCA2, 3 and 6 were referred as single cases, while many positive 
for SCA1 or 7 were referred as part of affected families (≥2 affected 
individuals). A single individual was diagnosed with SCA17. Molecular 
diagnostic testing for SCA17 was introduced in 2005, and is therefore 
excluded from the analysis of the full 24-year period.
Distribution of the polyglutamine SCAs among SA 
ethnic groups
SA has diverse population groups of different genetic origins; 79.5% 
are indigenous black Africans, 9% white, 9% coloured, and 2.5% of 
Indian or Asian ethnicity.6 The demographic information supplied 
with molecular diagnostic testing referrals to the UCT laboratory 
rarely contains detailed biographical or clinical information; therefore 
the ethnicity of 23.6% families is listed as ‘unknown’ (Table 3). Within 
this SA cohort, the coloured and white populations were most 
commonly diagnosed with SCA1, whereas the highest percentages of 
black African patients were diagnosed with SCA2 or 7. Individuals of 
Indian descent were exclusively affected with SCA1 or 2.
Distribution of repeat lengths
Figs 1 and 2 present the CAG repeat lengths of a subset of SCA1 and 
7 patients for whom data were available within the SA SCA patient 
population. Wild-type SCA1 alleles typically contain between 6 and 
38 repeats, where alleles with more than 39 repeats are classified as 
pathogenic.7 Within the SA SCA1 cohort, the most common wild-
type allele contained 30 CAG repeats (range of 27 - 36 repeats), 
whereas the most common pathogenic allele contained 47 repeats 
Table 3. Distribution of ethnicities among SA polyglutamine 
SCA families
Affected families (N)
Ethnicity SCA1 SCA2 SCA3 SCA6 SCA7 Total
Coloured 14 1 1 0 0 16
White 12 1 1 4 1 19
Indian 5 3 0 0 0 8
Black 3 30 1 0 49 83
Unknown 26 9 4 0 0 39
Fig. 1. Distribution of repeat lengths in SA SCA1 patients.
Fig. 2. Distribution of repeat lengths in SA SCA7 patients.
Table 1. Clinical findings in the more common types of SCA in the SA cohort*
Clinical features SCA1 SCA2 SCA6 SCA7
Gait ataxia + + + +
Limb ataxia + + + +
Dysarthria + + + +
Progressive disabling visual impairment +
Maculopathy +
Pigmentary retinopathy +
Supranuclear ophthalmoplegia + + +
Diplopia with inability to maintain ocular fixation +
Reduced smooth pursuit eye movements + +
Slow saccadic eye movements + +
Brisk tendon reflexes/spasticity + +
Sensory peripheral neuropathy + +
Cognitive impairment (late) + +
*SCA3 and SCA17 excluded owing to insufficient clinical data.
Table 2. Distribution of polyglutamine SCAs in SA
SCA patients N (%) SCA families N (%)
SCA1 119 (48.8) 60 (36.4)
SCA2 48 (19.7) 44 (26.7)
SCA3 8 (3.3) 7 (4.2)
SCA6 5 (2) 4 (2.4)
SCA7 65 (26.6) 50 (30.3)
Total 245 (100) 165 (100)
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(range of 42 - 66 repeats, Fig. 1). In SCA7, alleles with >36 repeats are 
classified as pathogenic, while wild-type alleles range in size from 4 to 
19 repeats.7 Alleles with 20 - 35 repeats are classified as intermediate 
alleles. Intermediate alleles are not pathogenic, but may pose a risk 
to the offspring of the carrier through meiotic expansion into the 
pathogenic range during vertical transmission.8 Within the SA SCA7 
patient group, the most common wild-type allele contained 12 CAG 
repeats (range of 7 - 14). The most frequent pathogenic allele length 
was 56, with a pathogenic range of 39 - 83 repeats (Fig. 2).
Discussion
The distribution of the polyglutamine SCAs in SA differs significantly 
from other countries. The incidence of the polyglutamine SCAs 
calculated here is likely to be an underestimation, since molecular 
diagnostic testing referrals from geographically remote areas and 
low-income communities are limited by absent infrastructure and 
financial constraints. Of concern is that almost 80% of patients referred 
for molecular diagnosis tested negative for the polyglutamine SCAs, 
highlighting that other (possibly undiagnosed) neurological disorders 
contribute to the health burden in SA. Diagnostic referral forms 
rarely contain family history information, so it is unclear whether 
these cases are sporadic or familial. If a significant proportion of them 
were found to be associated with a positive family history, appropriate 
measures could be undertaken to identify additional inherited 
neurological disorders that are common in SA. Future work is likely 
to include pilot studies to screen patients who have tested negative for 
the panel of 5 SCAs, for other SCAs. However, SA’s unique population 
composition presents difficulties in predicting the SCAs that are most 
likely to present in SA, since these may differ significantly from those 
seen internationally. SCA3 has been reported as the most common 
of the SCAs, accounting for the majority of ADCA cases in regions 
of Portugal, the Netherlands, Brazil, China, Japan and Germany.1 By 
contrast, SCA3 in SA was identified in only 8 individuals representing 
at least 3 ethnic groups over the 24-year period. SCA1 remains the 
most frequent polyglutamine SCA in SA,3 where it is overrepresented 
in the coloured and white population groups.
The frequency of the SCA7 mutation in SA remains one of the 
highest reported.3 SCA7 is the most common dominant ataxia in 
Sweden, Norway, Denmark and Finland, as a result of a founder 
effect.9 A similar experimental approach to that of the Jonasson et 
al. study9 identified a shared haplotype within the SA SCA7 patient 
cohort,10 which consists almost entirely of individuals of black African 
ancestry. Evidence from our research laboratory suggests that this SA 
SCA7 haplotype may be present in a SCA7 family native to northern 
Namibia, and a Zambian SCA7 patient, supporting the hypothesis that 
the founder effect may extend geographically into areas north of SA.
Similarly, 2 distinct haplotypes are associated with the SCA1 
mutation in the SA coloured patient population.11,12 The origin 
and extent of these haplotypes is being investigated; however, they 
are likely to be present in additional ethnic groups, owing to the 
heterogeneous composition of the coloured population.
Therapeutically, the shared haplotypes within a specific patient 
population may be significant, since they increase the likelihood 
of patients inheriting identical alleles with a single nucleotide 
polymorphism (SNP) in linkage disequilibrium with the disease-
causing mutation. Studies have demonstrated the utility of such 
disease-linked SNPs as targets for the design of allele-specific 
RNA interference (RNAi)-based therapies for both SCA112 and 
7,13 suggesting that allele-specific therapies may selectively silence 
mutant gene expression while retaining functional levels of the 
wild-type copy. Similar approaches are being considered for other 
neurological disorders such as Huntington’s disease.14
Information regarding trends in ethnicities may be valuable in 
the clinical diagnosis of the polyglutamine SCAs, particularly in 
cases where molecular diagnostic confirmation is not possible. 
Individuals of coloured ethnicity appear more likely to be affected 
with SCA1, possibly due to their two originating founder effects. 
White individuals are positive for all 5 types of polyglutamine 
SCA, with most individuals testing positive for SCA1. Individuals 
of Indian descent in SA have, to date, been solely identified with 
SCA1 or 2. Reports suggest higher distributions of SCA1 and 2 in 
various populations native to India, but there are additional reports 
of Indian individuals diagnosed with SCA3 or 6.15 Until recently, the 
SCA7 mutation was found exclusively in individuals of black African 
descent, with the SCA2 mutation arising at a similarly high frequency. 
The first white SA SCA7 patient was identified early in 2011. Owing 
to the lack of epidemiological studies on the African continent and 
within indigenous populations, it is not known whether these trends 
are representative of other African countries. Information regarding 
the occurrence of the polyglutamine SCAs in African countries is 
limited to reports from countries such as Mali.16
The size of the pathogenic CAG repeat in the polyglutamine SCAs 
is inversely correlated with the age of onset of symptoms and the 
rate of disease progression.8 Individuals with larger repeat lengths 
tend to develop symptoms at an earlier age, and progress at a faster 
rate than patients with smaller repeats. Therefore, knowing the 
repeat size of an affected SCA individual may aid in their clinical 
management. Historically, the exact repeat size of SCA patients has 
not been recorded as part of the diagnostic process, and therefore we 
could not comment on the distribution of repeat sizes in SA SCA2, 
3 and 6 patients. The UCT Division of Human Genetics has ongoing 
research projects on SCA1 and 7, which allowed for re-testing and 
sizing of the DNA banked for the SCA1 and 7 patient groups. The 
repeat size ranges for SA SCA1 and 7 patients lie within those of 
other population groups,7 although accurate repeat size data were 
available for only half of each patient cohort, since repeat sizes were 
not systematically recorded for the full 24-year period. The lack of 
large normal alleles in these groups (alleles within the normal range, 
but with a larger repeat length) also supports the hypothesis that the 
expanded alleles are prevalent because of a founder effect, rather 
than the independent expansion of large normal alleles. There is a 
close association between the frequency of large normal alleles and 
the prevalence of the SCAs within a given population,17 which may 
further explain the reduced prevalence of the polyglutamine SCAs 
in SA. However, detailed studies on repeat sizes of unaffected SA 
individuals are needed to support this hypothesis.
Our study encountered a paucity of information on ethnicity and 
CAG repeat-length data. This highlights the need for more detailed 
diagnostic reports and patient information to improve the accuracy of 
epidemiological studies and to assist in patient management. Detailed 
family history data should also be obtained where possible, as multi-
generation pedigrees greatly enhance the ability of researchers to 
assign haplotypes – a critical step in determining future eligibility for 
emerging RNAi-based therapies. Such research is hampered by the 
limited availability of biological samples from SCA patients and their 
unaffected family members. We therefore recommend that medical 
practitioners encourage SCA families to consider participation in 
molecular research studies.
Our reported frequency of the polyglutamine SCAs in SA reflects 
the unique population ethnic and geographical distribution. While 
there has been no significant change in trends of distribution of 
the polyglutamine SCAs in SA over the past 8 years, this report 
highlights the lack of patient information that accompanies molecular 
diagnostic referrals for genetic testing. Critical patient biographical 
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information, such as family history and ethnic background, will aid 
researchers to identify SA population trends, resulting in streamlined 
diagnostic strategies, improved clinical utility and validation of tests 
and, importantly, reduced costs. This information will also be crucial 
in identifying patients and families who may benefit from future 
RNAi-based gene silencing therapies.
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